TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Evogene ( (EVGN) ) has issued an update.
On August 18, 2025, Evogene Ltd. announced that its shareholders approved all proposals at the annual general meeting, which was held after a one-week adjournment. This approval, in accordance with Israeli Companies Law, signifies a strategic alignment with the company’s goals and may impact its operational strategies and stakeholder interests.
The most recent analyst rating on (EVGN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
Spark’s Take on EVGN Stock
According to Spark, TipRanks’ AI Analyst, EVGN is a Neutral.
Evogene’s overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and negative cash flow. While the company has made strategic moves to reduce expenses and execute acquisitions, these are offset by a significant revenue decline and the need for additional funding. Technical indicators suggest a bearish trend, and valuation metrics are unattractive due to ongoing losses.
To see Spark’s full report on EVGN stock, click here.
More about Evogene
Evogene Ltd. operates in the biotechnology industry, focusing on the development of products for life sciences markets, including agriculture, human health, and industrial applications. The company leverages its computational predictive biology platform to enhance product development processes.
Average Trading Volume: 1,849,454
Technical Sentiment Signal: Sell
Current Market Cap: $11.76M
See more insights into EVGN stock on TipRanks’ Stock Analysis page.